-
Imunon NASDAQ:IMNN Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
Location: 997 Lenox Dr Ste 100, New Jersey, 08648-2317, US | Website: www.celsion.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
11.06M
Cash
5.307M
Avg Qtr Burn
-4.656M
Short % of Float
2.80%
Insider Ownership
1.10%
Institutional Own.
11.06%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IMNN-001 (GEN-1) +/- bevacizumab Details Cancer, Ovarian cancer | Phase 1/2 Data readout | |
IMNN-101 Details COVID-19 | Phase 1 Data readout | |
ThermoDox Details Cancer, Liver cancer | Failed Discontinued |